The US Food and Drug Administration (FDA) has added a new warning to deoxycholic acid (Kybella, Allergan Aesthetics) due to serious adverse reactions associated with use of the injection outside of the submental fat region.
The FDA recommends against such unapproved uses.
The agency approved this revised labeling after its review of FDA Adverse Event Reporting System (FAERS) reports (now known as the FDA Adverse Event Monitoring System) and the medical literature.
In this review, the FDA determined that when deoxycholic acid is injected outside the submental fat region, neuromuscular and other serious adverse events may occur.
The FDA has also approved language in the Warnings and Precautions section of labeling about the serious risks of injection-site nodules and masses.
These newly identified risks are being added to information on other injection-site reactions already described in labeling. In this same FAERS review, the agency determined that there is an association between deoxycholic acid injection and reports of injection-site nodules (3cm or smaller) or masses (larger than 3cm), which may not resolve over time and may require medical intervention. Nodules and masses may occur when patients receive deoxycholic acid injections as indicated in the submental fat region and when patients receive injections of the drug outside the submental fat region.